Compare HAE & LGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAE | LGN |
|---|---|---|
| Founded | 1971 | 1963 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | 1996 | 2025 |
| Metric | HAE | LGN |
|---|---|---|
| Price | $119.47 | $51.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 17 |
| Target Price | ★ $111.50 | $102.53 |
| AVG Volume (30 Days) | 472.9K | ★ 806.5K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | $910,373,000.00 | ★ $2,550,491,000.00 |
| Revenue This Year | $6.21 | $87.60 |
| Revenue Next Year | $5.54 | $13.82 |
| P/E Ratio | $141.61 | ★ N/A |
| Revenue Growth | N/A | ★ 21.53 |
| 52 Week Low | $48.17 | $30.65 |
| 52 Week High | $110.45 | $107.24 |
| Indicator | HAE | LGN |
|---|---|---|
| Relative Strength Index (RSI) | 75.86 | 40.43 |
| Support Level | $72.93 | $48.60 |
| Resistance Level | N/A | $53.65 |
| Average True Range (ATR) | 2.90 | 2.46 |
| MACD | 0.07 | 0.26 |
| Stochastic Oscillator | 91.67 | 17.55 |
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.
Legence Corp is a provider of engineering, installation, and maintenance services for critical systems in buildings. It focuses on sectors that have technically demanding buildings, including technology, life sciences, healthcare, and education. Legence specializes in designing, fabricating, and installing complex heating, ventilation, and air conditioning (HVAC), process piping, and other mechanical, electrical, and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting, and building controls in existing facilities to enhance building performance, reliability, and efficiency. The services are mainly provided on a fixed price basis. The company has two reportable segments: Installation and Maintenance, which generates the maximum revenue, and Engineering and Consulting.